BioCentury
ARTICLE | Finance

More details, please

Actelion to focus on specialty indications; investors wanted more details

May 14, 2012 7:00 AM UTC

Investors were underwhelmed last week after Actelion Ltd. (SIX:ATLN) outlined plans to return to earnings growth.

Actelion fell CHF0.80 to CHF39.10, after gaining 14% the prior week on positive Phase III data for macitentan to treat pulmonary arterial hypertension (see BioCentury, May 7). ...